Drugs Generic: Forest Laboratories (NYSE:FRX), Mylan Inc (NASDAQ:MYL), Zoetis Inc (NYSE:ZTS), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Actavis plc (NYSE:ACT)

Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX), announced that the U.S. Federal Trade Commission (FTC) has voted to approve Actavis’ proposed acquisition of Forest. The vote in support of the transaction follows Actavis and Forest’s agreement to a proposed consent order, pursuant to which the companies have agreed to divest certain products as a condition to obtaining FTC approval. The closing of the transaction remains subject to other customary closing conditions, and is expected to be effective on July 1, 2014. Forest Laboratories, Inc. (NYSE:FRX), net profit margin is 4.50% and weekly performance is 0.25%. Analysts mean target price for the company is $93.57. Forest Laboratories, Inc. (NYSE:FRX), distance from 50-day simple moving average (SMA50) is 5.10%.

Mylan Inc (NASDAQ:MYL), announced that it will host a conference call and live webcast on Thursday, Aug. 7, 2014, at 10:00 a.m. ET to review the company’s financial results for the second quarter and first half ended June 30, 2014. Mylan will release its financial results on Aug. 7 before the market opens. Mylan Inc (NASDAQ:MYL), advanced 0.48% in last trading session and ended the day on $52.14. MYL, Gross Margin is 44.80% and its return on assets is 4.50%. Mylan Inc (NASDAQ:MYL), quarterly performance is 2.70%.

On June 30, 2014, Zoetis Inc (NYSE:ZTS), will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, August 5, 2014. Chief Executive Officer Juan Ramón Alaix and Senior Vice President of Finance Operations and Acting Chief Financial Officer Glenn David will review second quarter 2014 financial results and respond to questions from financial analysts during the call. Zoetis Inc (NYSE:ZTS), shares moved up 0.71% in last trading session and was closed at $32.74, while trading in range of $32.50 – 32.76. Zoetis Inc (NYSE:ZTS), year to date (YTD) performance is 0.61%.

On June 30, 2014, Avanir Pharmaceuticals Inc (NASDAQ:AVNR), announced that data related to pseudobulbar affect (PBA), a neurological condition characterized by disruptive, uncontrollable episodes of laughing or crying, and NUEDEXTA(R) (dextromethorphan hydrobromide/quinidine sulfate), the only FDA-approved product for the treatment of PBA, will be presented at the Alzheimer’s Association International Conference (AAIC), being held at the Bela Center in Copenhagen, Denmark, July 12-17, 2014. Avanir Pharmaceuticals Inc (NASDAQ:AVNR), ended the last trading day at $5.73. Company weekly volatility is calculated as 2.86% and price to cash ratio as 18.19. Avanir Pharmaceuticals Inc (NASDAQ:AVNR), showed a positive weekly performance of 6.11%.

Actavis plc (NYSE:ACT), announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc.(NASDAQ: FURX) in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex’s lead product, as a controlled drug following approval. Actavis plc (NYSE:ACT), net profit margin is -5.80% and weekly performance is -0.51%. On last trading day company shares ended up $221.70. Analysts mean target price for the company is $254.28. Actavis plc (NYSE:ACT), distance from 50-day simple moving average (SMA50) is 5.66%.